Alert Added Successfully

Endocrinology


               
Article Title Year Authour(s) Journal Subject Expert Rating Evidence Ranking
1. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial 2006 Jackson, R.D. J Bone Miner Res Endocrinology A
2. Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Thirty-Six–Month Results of a Randomized, Double-Blind, Controlled Trial 2009 Saag, K...G..., Zanchetta, J...R..., Devogelaer, J...-.P... Arthritis Rheum Endocrinology A
3. Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men 2006 Finkelstein, J.S., Leder, B.Z., Burnett, S.A.M. J Clin Endocrinol Metab Endocrinology A
4. The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women 2009 Grey, A..., Bolland, M...J..., Wattie, D... J Clin Endocrinol Metab Endocrinology B
5. Calcium plus Vitamin D Supplementation and the Risk of Fractures 2006 Jackson, R.D. N Engl J Med Endocrinology A
6. Osteocalcin Expression by Circulating Endothelial Progenitor Cells in Patients With Coronary Atherosclerosis 2008 Gössl, M..., Mödder, U...I..., Atkinson, E...J... J Am Coll Cardiol Endocrinology B
7. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial 2009 Reid, D...M..., for the HORIZON investigators. Lancet Endocrinology A
8. Effect of Cholecalciferol Plus Calcium on Falling in Ambulatory Older Men and Women: A 3-Year Randomized Controlled Trial 2006 Bischoff-Ferrari, H.A., Orav, E.J., Dawson-Hughes, B. Arch Intern Med Endocrinology A
9. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial 2009 Wardlaw, D..., Cummings, S...R..., Van Meirhaeghe, J... Lancet Endocrinology A
10. Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate 2005 Cosman, F., Nieves, J., Zion, M. N Engl J Med Endocrinology A
11. Systematic Review: Biphosphonates and Osteonecrosis of the Jaws 2006 Woo, S.B., Hellstein, J.W., Kalmar, J.R. Ann Intern Med Endocrinology E
12. Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate 2008 Miller, P...D..., Delmas, P...D..., Lindsay, R... J Clin Endocrinol Metab Endocrinology B
13. Thiazolidenedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus 2010 Habib, Z...A..., Havstad, S...L..., Wells, K... J Clin Endocrinol Metab Endocrinology B
14. Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis 2005 Chen, P., Satterwhite, J.H., Licata, A.A. J Bone Miner Res Endocrinology A
15. Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates 2008 Hoff, A...O..., Toth, B...B..., Altundag, K... J Bone Miner Res Endocrinology B
16. Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis 2009 Leder, B...Z..., Neer, R...M..., Wyland, J...J... J Clin Endocrinol Metab Endocrinology B
17. Effects of Yearly Zoledronic Acid 5mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis 2009 Delmas, P...D..., Munoz, F..., Black, D...M... J Bone Miner Res Endocrinology A
18. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer 2009 Smith, M...R..., for the Denosumab HALT Prostate Cancer Study Group. N Engl J Med Endocrinology A
19. Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Three Cases of Fibroblastic Osteosarcoma 2005 Jimenez, C., Yang, Y., Kim, H.W. J Bone Miner Res Endocrinology B
20. Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis 2009 Recker, R...R..., Marin, F..., Ish-Shalom, S... J Bone Miner Res Endocrinology B
21. Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy 2009 Weinstein, R...S..., Roberson, P...K..., Manolagas, S...C... N Engl J Med Endocrinology A
22. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes 2010 Zinman, B..., Haffner, S...M..., Herman, W...H... J Clin Endocrinol Metab Endocrinology A
23. Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6-Month Double-Blind Placebo-Controlled Trial 2005 Deal, C., Omizo, M., Schwartz, E.N. J Bone Miner Res Endocrinology A
24. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs 2006 Kavanagh, K.L., Guo, K., Dunford, J.E. Proc Natl Acad Sci U S A Endocrinology E
25. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial 2009 Reid, D...M..., for the HORIZON investigators. Lancet Endocrinology A
26. Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study 2005 Miller, P.D., McClung, M.R., Macovei, L. J Bone Miner Res Endocrinology A
27. One Year of Alendronate After One Year of Parathyroid Hormone (1–84) for Osteoporosis 2005 Black, D.M., for the PaTH Study Investigators. N Engl J Med Endocrinology A
28. Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis 2006 Bauer, D.C. J Clin Endocrinol Metab Endocrinology A
29. Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users 2008 Curtis, J...R..., Westfall, A...O..., Cheng, H... J Bone Miner Res Endocrinology B
30. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study 2006 Reginster, J.Y., Adami, S., Lakatos, P. Ann Rheum Dis Endocrinology A
31. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial 2009 Reid, D...M..., Devogelaer, J...-.P..., Saag, K... Lancet Endocrinology A
32. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial 2006 Bauer, D.C. J Bone Miner Res Endocrinology A
33. A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures 2009 Kallmes, D...F..., Comstock, B...A..., Heagerty, P...J... N Engl J Med Endocrinology A
34. Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent 2009 Cosman, F..., Wermers, R...A..., Recknor, C... J Clin Endocrinol Metab Endocrinology B
35. Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years 2006 Bonnick, S. J Clin Endocrinol Metab Endocrinology A